THE ROLE OF Treg CELLS AND FoxP3 EXPRESSION IN IMMUNITY OF β-THALASSEMIA MAJOR AND β-THALASSEMIA TRAIT PATIENTS

被引:22
作者
Bozdogan, Gunseli [1 ]
Erdem, Ela [3 ]
Demirel, Gulderen Yanikkaya [2 ]
Yildirmak, Yildiz
机构
[1] Acibadem Hosp, Dept Pediat Allergy & Immunol, Acibadem Healthcare Grp, Istanbul, Turkey
[2] Ctr Lab, Immunohematol Sect, Istanbul, Turkey
[3] Sisli Etfal Educ & Res Hosp, Dept Pediat Hematol, Pediat Clin, Istanbul, Turkey
关键词
children; FoxP3; lymhocyte subsets; thalassemia; Treg cells; REGULATORY T-CELLS; LYMPHOCYTE SUBSETS; PERIPHERAL-BLOOD; ABNORMALITIES; INCREASE; CHILDREN;
D O I
10.3109/08880018.2010.503334
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
There is increased susceptibility to infections in beta-thalassemia. Changes in T-and B-lymphocyte subsets and functions, defective chemotaxis, and phagocytosis of neutrophils and macrophages have been described in these patients. Regulatory T cells (Treg cells) play a crucial role in the maintenance of immunological self-tolerance. The FOXP3 gene is specifically expressed on Treg cells. Increased antigenic stimuli due to repeated blood transfusions might change the Treg cells and FOXP3 percentage in beta-thalassemia. Immune functions of peripheral blood lymphocytes, percentage of Treg cells (defined as CD4(+) CD25(+) FoxP3(+)) were evaluated in 30 beta-thalassemia major, 30 beta-thalassemia trait, and 20 healthy children. Percentage of CD4+ CD45RA(+) cells were increased in beta-thalassemia trait compared to both beta-thalassemia major and controls, whereas percentage of CD4(+) CD45RO(+) cells were higher in beta-thalassemia major and trait patient compared to controls. Percentages of CD4(+) CD25(bright) and CD4(+) CD25(+) FoxP3(+) Treg cells were increased only in beta-thalassemia major patients compared to controls (P = .001 and P = .0001, respectively). T lymphocytes express activated phenotype both in beta-thalassemia major and trait patients. However, only in beta-thalassemia
引用
收藏
页码:534 / 545
页数:12
相关论文
共 31 条
[1]
AKBAR AN, 1985, CLIN EXP IMMUNOL, V62, P397
[2]
ARCASOY A, 1982, P THAL S MED RES GRO, P3
[3]
Survival and disease complications in thalassemia major [J].
Borgna-Pignatti, C ;
Rugolotto, S ;
De Stefano, P ;
Piga, A ;
Di Gregorio, F ;
Gamberini, MR ;
Sabato, V ;
Melevendi, C ;
Cappellini, MD ;
Verlato, G .
COOLEYS ANEMIA: SEVENTH SYMPOSIUM, 1998, 850 :227-231
[4]
Immunological evaluation of patients with beta-thalassemia major [J].
Consolini, R ;
Calleri, A ;
Legitimo, A ;
Massei, F .
ACTA HAEMATOLOGICA, 2001, 105 (01) :7-12
[5]
How do Regulatory T Cells Work? [J].
Corthay, A. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2009, 70 (04) :326-336
[6]
DeBaun MR, 2007, NELSON TXB PEDIAT, P2025
[7]
Effects of deferiprone on immune status and cytokine pattern in thalassaemia major [J].
Del Vecchio, GC ;
Schettini, F ;
Piacente, L ;
De Santis, A ;
Giordano, P ;
De Mattia, D .
ACTA HAEMATOLOGICA, 2002, 108 (03) :144-149
[8]
Dua D, 1993, Indian Pediatr, V30, P893
[9]
DWYER J, 1987, CLIN EXP IMMUNOL, V68, P621
[10]
Immunological status of thalassemia syndrome [J].
Ezer, U ;
Gülderen, F ;
Çulha, VK ;
Akgül, N ;
Gürbüz, O .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2002, 19 (01) :51-58